Design Therapeutics

NSQ:DSGN · US25056L1035

BiotechnologySmall

360° View

Value26

Price/Sales—

Price/Earnings68

Price/Book33

Dividend Yield1

Growth87

Revenue Growth—

Profit Growth70

Capital Growth66

TSR 52w83

Safety70

Leverage84

Liquidity26

Refinancing55

Combined78

Sentiment55

Analyst Opinions42

Pro Holdings45

Opinion Changes93

Market Pulse42

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2017

Employees51

Websitedesigntx.com

ISINUS25056L1035

Last UpdateApr 2, 2026

Index & Theme

Health DiagnosticsPsychiatryGeneticsCardiovascularOphthalmologyNeurologyCentral Nervous SystemNeuroscienceGenetic DisorderBiotechnologyLife ScienceMedical

Description

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to…

Analysis

Design Therapeutics's 360° View rank of 71 places it above its peer average — better than 71% of its true peers.

It's a growth standout (87) and on the expensive side (26). On safety it is financially sound (70), and the market shows favorable sentiment (55). Taken together, its Combined rank of 78 reads as among the strongest overall.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Design Therapeutics with its peers

Larimar Therapeutics

NMQ:LRMR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Elicio Therapeutics

NAQ:ELTX

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

MeiraGTx

NSQ:MGTX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Viking Therapeutics

NAQ:VKTX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

ImageneBio

NAQ:IMA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Acumen Pharmaceuticals

NSQ:ABOS

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →